Arbutus Biopharma Corp (FRA:I9DN)
€ 3.742 -0.194 (-4.93%) Market Cap: 692.09 Mil Enterprise Value: 598.69 Mil PE Ratio: 0 PB Ratio: 6.56 GF Score: 47/100

Q3 2020 Arbutus Biopharma Corp Earnings Call Transcript

Nov 05, 2020 / 01:45PM GMT
Release Date Price: €2.5 (+1.79%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to Arbutus Biopharma Corporation 2020 Third Quarter Financial Results and Corporate Update. (Operators Instruction]. As a reminder, this conference is being recorded. I would now like to hand the conference over to Pam Murphy, you may begin.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Good morning and thank you for joining Arbutus' Third Quarter 2020 Conference Call. On the call today are William Collier, President and Chief Executive Officer; Dr. Mike Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer and Dave Hastings, Chief Financial Officer.

Bill will begin with a summary of recent accomplishments and upcoming events and a review of Arbutus' corporate objectives followed by Dave Hastings who will provide a quick recap of Arbutus' key third-quarter financial results. We'll then open the call for Q&A. Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot